Skip to Content

Becton, Dickinson and Co BDX Stock Quote

| Rating as of

Morningstar‘s Stock Analysis BDX

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Becton, Dickinson's 2022 Success Depends on Alaris

Alex Morozov, CFA Regional Director

Business Strategy and Outlook

| Alex Morozov, CFA |

While 2020 was a challenging year for Becton, Dickinson, or BD, 2021 has been better, buoyed by Veritor demand in particular. Much uncertainty resides in the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company that will see some challenging comps as testing revenue wanes.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BDX

Company Profile BDX

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Contact
1 Becton Drive
Franklin Lakes, NJ, 07417-1880
T +1 201 847-6800
Industry Medical Instruments & Supplies
Most Recent Earnings Jun 30, 2022
Fiscal Year End Sep 30, 2022
Employees 75,000

Related News BDX